Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novus Therapeutics Inc. (NVUS)

0.95   -0.03 (-3.09%) 10-01 08:55
Open: 1.02 Pre. Close: 0.9803
High: 1.02 Low: 0.9401
Volume: 321,454 Market Cap: 22M
Novus Therapeutics Inc. engages in the research and development of pharmaceutical products for patients with disorders of the ear, nose, and throat. The company is headquartered in Irvine, California and currently employs 10 full-time employees. The firm is focused on the acquisition, development, and commercialization of ear, nose, and throat products. The company has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.051 - 1.058 1.058 - 1.064
Low: 0.957 - 0.964 0.964 - 0.97
Close: 0.98 - 0.992 0.992 - 1.001

Technical analysis

as of: 2020-09-30 4:44:46 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.58     One year: 1.84
Support: Support1: 0.73    Support2: 0.34
Resistance: Resistance1: 1.35    Resistance2: 1.58
Pivot: 0.81
Moving Average: MA(5): 0.96     MA(20): 0.70
MA(100): 0.61     MA(250): 0.57
MACD: MACD(12,26): 0.14     Signal(9): 0.12
Stochastic oscillator: %K(14,3): 62.49     %D(3): 61.29
RSI: RSI(14): 70.44
52-week: High: 1.45  Low: 0.25  Change(%): 75.8
Average Vol(K): 3-Month: 396144  10-Days: 226715

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
NVUS has closed below upper band by 32.3%. Bollinger Bands are 152.5% wider than normal. The large width of the bands suggest high volatility as compared to NVUS's normal range. The bands have been in this wide range for 10 bars. This is a sign that the current trend might continue.

Headline News

Tue, 29 Sep 2020
Where Will Novus Therapeutics Inc (NVUS) Stock Go Next After It Is Higher By 5.15% in a Week? - InvestorsObserver

Mon, 28 Sep 2020
Novus Therapeutics, Inc. (NVUS) Bears Seem To Be Pulling The Price Back - Invest Million

Sat, 26 Sep 2020
Short term estimates and forecasts for Novus Therapeutics, Inc. (NVUS) - Marketing Sentinel

Thu, 24 Sep 2020
Analysts Offer Important Insight on Novus Therapeutics, Inc. (NVUS) - Stocks Register

Tue, 22 Sep 2020
Highlights from the Ratings and Financial Report for Novus Therapeutics Inc. (NVUS) - The News Heater

Tue, 22 Sep 2020
Novus Therapeutics, Inc. (NASDAQ:NVUS) surprises Wall Street with 0.18% stock price gain - Marketing Sentinel

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 23
Shares Float (M) 15
% Held by Insiders 4.59
% Held by Institutions 35.11
Shares Short (K) 211
Shares Short P. Month (K) 178

Stock Financials

EPS -1.182
EPS Est This Year -9.990
EPS Est Next Year -0.390
Book Value (p.s.) 0.480
Profit Margin
Operating Margin
Return on Assets (ttm) -46.6
Return on Equity (ttm) -140.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.460
Qtrly Earnings Growth
Operating Cash Flow (M) -10
Levered Free Cash Flow (M) -6

Stock Valuations

PE Ratio -0.84
PEG Ratio
Price to Book value 2.06
Price to Sales
Price to Cash Flow -2.27

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.